{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T09:25:00Z","timestamp":1786958700151,"version":"build-2736575974"},"reference-count":51,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T00:00:00Z","timestamp":1786838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Type 2 diabetes mellitus (T2DM) is often linked to metabolic dysfunction-associated steatotic liver disease (MASLD), a metabolic liver condition defined by excessive lipid deposition within hepatocytes and is frequently accompanied by increased circulating liver enzyme levels. Dipeptidyl peptidase-4 (DPP-4) inhibitors, such as linagliptin, may exert pleiotropic effects on hepatic metabolism; however, their effects on liver enzyme profiles remain uncertain. This systematic review and meta-analysis aimed to evaluate the impact of linagliptin on liver enzymes, including aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), and gamma-glutamyl transferase (GGT), in patients with T2DM. A systematic literature search was performed across five electronic databases up to 11 May 2026 following the PRISMA 2020 guidelines. Randomized controlled trials and cohort studies were included, and pooled mean differences (MDs) were calculated using random-effects models. Eight studies involving 1262 participants were analyzed. Linagliptin was associated with a modest reduction in AST (MD \u22121.58 U\/L, 95% CI \u22122.85 to \u22120.31) with low heterogeneity, whereas the change in ALT was not statistically significant (MD \u22121.86 U\/L, 95% CI \u22124.14 to 0.42), and substantial heterogeneity was observed. No significant effects were observed for GGT, while evidence for ALP was limited to a single study and was insufficient to determine the effect of linagliptin. Overall, linagliptin demonstrated limited and inconsistent effects on liver enzyme profiles.<\/jats:p>","DOI":"10.3390\/life16081343","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T08:05:41Z","timestamp":1786953941000},"page":"1343","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of Linagliptin on Liver Enzymes in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3264-1155","authenticated-orcid":false,"given":"Moragot","family":"Chatatikun","sequence":"first","affiliation":[{"name":"Department of Medical Technology, School of Allied Health Sciences, Walailak University, Nakhon Si Thammarat 80160, Thailand"},{"name":"Biomedical Sciences and Health Innovations (International Program), School of Allied Health Sciences, Walailak University, Nakhon Si Thammarat 80160, Thailand"},{"name":"Research Excellence Center for Innovation and Health Products (RECIHP), Walailak University, Nakhon Si Thammarat 80160, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5418-8540","authenticated-orcid":false,"given":"Ratana","family":"Netphakdee","sequence":"additional","affiliation":[{"name":"Biomedical Sciences and Health Innovations (International Program), School of Allied Health Sciences, Walailak University, Nakhon Si Thammarat 80160, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aman","family":"Tedasen","sequence":"additional","affiliation":[{"name":"Department of Medical Technology, School of Allied Health Sciences, Walailak University, Nakhon Si Thammarat 80160, Thailand"},{"name":"Biomedical Sciences and Health Innovations (International Program), School of Allied Health Sciences, Walailak University, Nakhon Si Thammarat 80160, Thailand"},{"name":"Research Excellence Center for Innovation and Health Products (RECIHP), Walailak University, Nakhon Si Thammarat 80160, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9286-1786","authenticated-orcid":false,"given":"Jason C.","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Biotechnology and Laboratory Science in Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiyada Kwanhian","family":"Klangbud","sequence":"additional","affiliation":[{"name":"Medical Technology Program, Faculty of Science, Nakhon Phanom University, Nakhon Phanom 48000, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4542-8980","authenticated-orcid":false,"given":"Jongkonnee","family":"Thanasai","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Mahasarakham University, Mahasarakham 44000, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atthaphong","family":"Phongphithakchai","sequence":"additional","affiliation":[{"name":"Nephrology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2026). Standards of care in diabetes\u20142026. Diabetes Care, 49, S1\u2013S330.","DOI":"10.2337\/dc26-SDIS"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"15019","DOI":"10.1038\/nrdp.2015.19","article-title":"Type 2 diabetes mellitus","volume":"1","author":"DeFronzo","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_3","first-page":"578","article-title":"Non-alcoholic fatty liver disease: A multisystem disease requiring a multidisciplinary and holistic approach","volume":"6","author":"Targher","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_4","first-page":"9","article-title":"Non alcoholic fatty liver disease and metabolic syndrome","volume":"13","author":"Paschos","year":"2009","journal-title":"Hippokratia"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2024). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J. Hepatol., 81, 492\u2013542.","DOI":"10.1016\/j.jhep.2024.04.031"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH)","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/jdi.13756","article-title":"Non-alcoholic fatty liver disease and type\u20092 diabetes: An update","volume":"13","author":"Lee","year":"2022","journal-title":"J. Diabetes Investig."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2025). Standards of care in diabetes\u20142025. Diabetes Care, 48, S1\u2013S320.","DOI":"10.2337\/dc25-SDIS"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1503\/cmaj.1040752","article-title":"Liver enzyme alteration: A guide for clinicians","volume":"172","author":"Giannini","year":"2005","journal-title":"Can. Med. Assoc. J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1056\/NEJM200004273421707","article-title":"Evaluation of abnormal liver-enzyme results in asymptomatic patients","volume":"342","author":"Pratt","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Gallwitz, B. (2019). Clinical Use of DPP-4 Inhibitors. Front. Endocrinol., 10.","DOI":"10.3389\/fendo.2019.00389"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Deacon, C.F. (2019). Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes. Front. Endocrinol., 10.","DOI":"10.3389\/fendo.2019.00080"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e70277","DOI":"10.1002\/pds.70277","article-title":"Dipeptidyl peptidase 4 inhibitors: Novel therapeutic agents in the management of type II diabetes mellitus","volume":"34","author":"Aloke","year":"2025","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/DMSO.S23166","article-title":"Emerging DPP-4 inhibitors: Focus on linagliptin for type 2 diabetes","volume":"6","author":"Gallwitz","year":"2013","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"534","DOI":"10.4239\/wjd.v7.i19.534","article-title":"Linagliptin alleviates fatty liver disease in diabetic db\/db mice","volume":"7","author":"Michurina","year":"2016","journal-title":"World J. Diabetes"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Okuyama, T., Shirakawa, J., Tajima, K., Ino, Y., Vethe, H., Togashi, Y., Kyohara, M., Inoue, R., Miyashita, D., and Li, J. (2020). Linagliptin ameliorates hepatic steatosis via non-canonical mechanisms in mice treated with a dual inhibitor of insulin receptor and IGF-1 receptor. Int. J. Mol. Sci., 21.","DOI":"10.22541\/au.158878888.83136023"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Kern, M., Kl\u00f6ting, N., and Niessen, H.G. (2012). Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0038744"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00795-013-0053-9","article-title":"Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis","volume":"47","author":"Klein","year":"2014","journal-title":"Med. Mol. Morphol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014A web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"276","DOI":"10.11613\/BM.2012.031","article-title":"Interrater reliability: The kappa statistic","volume":"22","author":"McHugh","year":"2012","journal-title":"Biochem. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Gualdi-Russo, E., and Zaccagni, L. (2026). The Newcastle\u2013Ottawa scale for assessing the quality of studies in systematic reviews. Publications, 14.","DOI":"10.3390\/publications14010004"},{"key":"ref_24","unstructured":"Viswanathan, M., Ansari, M.H., Berkman, N.D., Chang, S., Hartling, L., McPheeters, M.L., and Santaguida, P.L. (2012). Assessing the Risk of Bias of Individual Studies in Systematic Reviews of Health Care Interventions, Agency for Healthcare Research and Quality (US)."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jclinepi.2010.07.017","article-title":"GRADE guidelines: 4. Rating the quality of evidence\u2014Study limitations (risk of bias)","volume":"64","author":"Guyatt","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1177\/0962280216669183","article-title":"Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range","volume":"27","author":"Luo","year":"2018","journal-title":"Stat. Methods Med. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control. Clin. Trials"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/sim.10008","article-title":"Sensitivity analysis with iterative outlier detection for systematic reviews and meta-analyses","volume":"43","author":"Meng","year":"2024","journal-title":"Stat. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/2047487320939217","article-title":"Effects of linagliptin on left ventricular DYsfunction in patients with type 2 DiAbetes and concentric left ventricular geometry: Results of the DYDA 2 trial","volume":"28","author":"Cioffi","year":"2021","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.diabres.2016.09.014","article-title":"Effects of linagliptin monotherapy compared with voglibose on postprandial blood glucose responses in Japanese patients with type 2 diabetes: Linagliptin Study of Effects on Postprandial blood glucose (L-STEP)","volume":"121","author":"Fujitani","year":"2016","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4239\/wjd.v9.i10.165","article-title":"Efficacy of anagliptin as compared to linagliptin on metabolic parameters over 2 years of drug consumption: A retrospective cohort study","volume":"9","author":"Hamasaki","year":"2018","journal-title":"World J. Diabetes"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s13300-018-0539-5","article-title":"The effect of linagliptin versus metformin treatment related quality of life in patients with type 2 diabetes mellitus","volume":"10","author":"Mita","year":"2019","journal-title":"Diabetes Ther."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Nishida, Y., Takahashi, Y., Tezuka, K., Akimoto, H., Nakayama, T., and Asai, S. (2020). Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus. BMC Pharmacol. Toxicol., 21.","DOI":"10.1186\/s40360-020-00407-4"},{"key":"ref_37","first-page":"1407","article-title":"Comparison of glimepiride and linagliptin in the treatment of non-alcoholic hepatic disease with type 2 diabetes mellitus","volume":"20","author":"Tian","year":"2023","journal-title":"Arch. Med. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12933-018-0716-x","article-title":"Effects of linagliptin on endothelial function and postprandial lipids in coronary artery disease patients with early diabetes: A randomized, placebo-controlled, double-blind trial","volume":"17","author":"Tripolt","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.12659\/MSM.894026","article-title":"Effect of linagliptin on glycemic control in Chinese patients with newly-diagnosed, drug na\u00efve type 2 diabetes mellitus: A randomized controlled trial","volume":"21","author":"Wu","year":"2015","journal-title":"Med. Sci. Monit."},{"key":"ref_40","first-page":"ED000142","article-title":"Updated guidance for trusted systematic reviews: A new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"100768","DOI":"10.1016\/j.curtheres.2024.100768","article-title":"Impact of dipeptidyl peptidase-4 inhibitors on aminotransferases levels in patients with type 2 diabetes mellitus with nonalcoholic fatty liver disease: A meta-analysis of randomized controlled trial","volume":"102","author":"Ma","year":"2025","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4239\/wjd.v12.i1.84","article-title":"Novel glucose-lowering drugs for non-alcoholic fatty liver disease","volume":"12","author":"Fu","year":"2021","journal-title":"World J. Diabetes"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"101970","DOI":"10.1016\/j.clinre.2022.101970","article-title":"Effect of novel glucose lowering agents on non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"46","author":"Zafar","year":"2022","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Kongmalai, T., Srinonprasert, V., Anothaisintawee, T., Kongmalai, P., McKay, G., Attia, J., and Thakkinstian, A. (2023). New anti-diabetic agents for the treatment of non-alcoholic fatty liver disease: A systematic review and network meta-analysis of randomized controlled trials. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1182037"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.2147\/DMSO.S369712","article-title":"Potential effect of DPP-4 inhibitors towards hepatic diseases and associated glucose intolerance","volume":"15","author":"Sharma","year":"2022","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.12659\/MSM.890989","article-title":"DPP-4 inhibitors improve liver dysfunction in type 2 diabetes mellitus","volume":"20","author":"Kanazawa","year":"2014","journal-title":"Med. Sci. Monit."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Haxhi, J., Vitale, M., Mattia, L., Giuliani, C., Sacchetti, M., Orlando, G., Iacobini, C., Menini, S., Zanuso, S., and Nicolucci, A. (2024). Effect of sustained decreases in sedentary time and increases in physical activity on liver enzymes and indices in type 2 diabetes. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1393859"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"890","DOI":"10.4093\/dmj.2020.0208","article-title":"Increased visit-to-visit liver enzyme variability is associated with incident diabetes: A community-based 12-year prospective cohort study","volume":"45","author":"Bang","year":"2021","journal-title":"Diabetes Metab. J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00535-013-0783-4","article-title":"Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats","volume":"49","author":"Kaji","year":"2014","journal-title":"J. Gastroenterol."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/8\/1343\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T08:33:41Z","timestamp":1786955621000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/8\/1343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,16]]},"references-count":51,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["life16081343"],"URL":"https:\/\/doi.org\/10.3390\/life16081343","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,16]]}}}